Previous 10 | Next 10 |
NEW YORK , Oct. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that on October 2, 2019 , the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 100,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by ...
An Emerging Markets News Commentary ORLANDO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- When Botox hit the annals of pop culture as a beauty product, a healer, and more it was shocking to many. How could a product derived from the notorious toxin Clostridium botulinum, the stuff that causes...
NEW YORK , Oct. 1, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes , today released a letter to shareholders. Dear Fellow Shareholders, As previously stated, Spherix is moving forward diligently with the dividend distribution. ...
NEW YORK , Sept. 25, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes , today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. Dear Fellow Shareholders, I want...
NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Maryland, Baltimore (UMB) related to its anticancer drug designated PrAg-PAS, a novel protein ...
NEW YORK , Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor. ...
NEW YORK , Sept. 9, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced results from the Special Meeting of Shareholders held on September 5th (the "Meeting"). At the Meeting, the Company's shareholders approved the issuance of shares of our Common Stock, ...
NEW YORK , Aug. 19, 2019 /PRNewswire/ -- Spherix Incorporated, (NASDAQ: SPEX) a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders: Dear Shareholder, In advance of our Special Meeting on September 5...
NEW YORK , June 26, 2019 /PRNewswire/ -- CBM BioPharma Inc. ("CBM") today announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance and Issue Fee Due in CBM's patent application related to the treatment of pancreatic cancer. CBM has r...
NEW YORK , June 19, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has filed a Preliminary Proxy Statement with the Securities and Exchange Commission and announced a Special Meeting of Stockholders related to approving various items related to the propos...
News, Short Squeeze, Breakout and More Instantly...
AIkido Pharma Company Name:
SPEX Stock Symbol:
NASDAQ Market:
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Fin...
ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. ...
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin ® program in cystic fi...